Conversations around GLP-1s in today’s healthcare market are mixed. Some stakeholders are thrilled with their potential, while others are filled with questions and even anxiety about how these powerful and popular drugs will impact their business. Many in the industry have been asking for months: “What can GLP-1s do?” But maybe this is the wrong question. Leaders should be asking “What CAN’T GLP-1s do?”

To answer that question, live from HLTH 2024, host Rachel (Rae) Wood invites Rob MacNaughton, CEO of lifestyle intervention and obesity management organization Calibrate, Rita Glaze-Rowe, President at life sciences research organization Real Chemistry, and Dr. Spencer Nadolsky, lipid and obesity specialist and founder to break down the cross-industry perspective on GLP-1s and how the healthcare leaders should be thinking about both the potential and limitations of these novel therapies. In a market that is buzzing around the novel medications, these experts suggest a new focus on comprehensive weight management programs.

Links:

Join 165,000+ healthcare leaders and get the industry’s most important news in your inbox—every day.

What the 2024 elections mean for healthcare

[Webinar, 10/24] How the 2024 elections could impact the healthcare industry

A transcript of this episode as well as more information and resources can be found on www.advisory.com/RadioAdvisory.

229: Live from HLTH: What Can’t GLP-1s Do?

Radio Advisory

229: Live from HLTH: What Can’t GLP-1s Do?